Abivax SA American Depositary Shares
$ 130.93
0.72%
07 Aug - close price
- Market Cap 11,330,888,000 USD
- Current Price $ 130.93
- High / Low $ 133.52 / 130.01
- Stock P/E N/A
- Book Value 6.24
- EPS -5.50
- Next Earning Report 2026-09-14
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.45 %
- ROE -1.57 %
- 52 Week High 148.83
- 52 Week Low 67.15
About
Abivax SA is a clinical-stage biotechnology firm focused on pioneering immunotherapies for chronic inflammatory diseases and viral infections. Its lead candidate, ABX464, is in advanced clinical trials targeting ulcerative colitis, utilizing a novel approach that integrates antibody-mediated therapies with proprietary compounds. Backed by a robust pipeline and an experienced scientific team, Abivax is strategically positioned to meet substantial unmet medical needs, making it an attractive prospect for institutional investors aiming to engage with the growing immunotherapy landscape.
Analyst Target Price
$165.91
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-22 | 2026-03-23 | 2025-12-15 | 2025-09-08 | 2025-06-02 | 2025-03-24 | 2024-11-07 | 2024-09-09 | 2024-04-02 | 2024-02-06 | 2023-11-29 | 2023-09-21 |
| Reported EPS | -0.71 | -1.18 | -2.47 | -0.89 | -0.95 | -0.8143 | -0.72 | -1.01 | -0.7903 | 0 | -0.64 | -0.72 |
| Estimated EPS | -0.81 | -1.04 | -0.79 | -0.95 | -0.76 | -1.29 | -0.79 | -0.97 | -0.6 | -0.92 | -0.64 | 0 |
| Surprise | 0.1 | -0.14 | -1.68 | 0.06 | -0.19 | 0.4757 | 0.07 | -0.04 | -0.1903 | 0.92 | 0 | -0.72 |
| Surprise Percentage | 12.3457% | -13.4615% | -212.6582% | 6.3158% | -25% | 36.876% | 8.8608% | -4.1237% | -31.7167% | 100% | 0% | None% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-09-14 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -1.08 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ABVX
2026-08-05 15:17:23
Capital Fund Management has revealed a 0.5% net short position in Abivax shares. This news brief was generated by Public Technologies using AI and is based on original content published by Abivax SA on August 5, 2026. The information provided is for informational purposes only and not financial advice.
2026-08-03 20:10:56
Militia Capital Management LLC has made a new investment in Abivax SA Sponsored ADR ($ABVX), purchasing 17,000 shares valued at approximately $1.89 million during the first quarter. Institutional investors collectively own 47.91% of Abivax, which holds a consensus "Moderate Buy" rating and an average price target of $156.50. The company recently reported better-than-expected quarterly results, and its lead drug candidate, obefazimod, is being tested for inflammatory diseases.
2026-08-02 10:40:46
Perceptive Advisors LLC reduced its stake in Abivax SA Sponsored ADR (NASDAQ:ABVX) by 28.2% in the first quarter, selling 129,459 shares but still retaining 328,884 shares valued at $36.6 million. Despite this reduction, institutional investors collectively own 47.91% of Abivax, and analysts maintain a "Moderate Buy" consensus rating with a target price of $156.50. The company exceeded quarterly earnings expectations, reporting an adjusted loss of $0.71 per share against an anticipated $0.94 loss and revenue of $1.56 million compared to estimates of $0.40 million.
2026-08-02 10:40:46
Seven Fleet Capital Management LP significantly increased its stake in Abivax SA Sponsored ADR (NASDAQ:ABVX) by 218.9% in the first quarter, now holding 43,052 shares valued at approximately $4.79 million. This makes Abivax 1.5% of their portfolio. Institutional investors collectively own 47.91% of Abivax, which has a "Moderate Buy" consensus rating and an average target price of $156.50 from analysts.
2026-08-02 06:39:53
Abivax SA Sponsored ADR (NASDAQ:ABVX) has received an average "Moderate Buy" recommendation from analysts, with 13 out of 15 analysts rating the stock a buy. The average 12-month price target is $156.50, significantly above its current $124.92 share price. Recent positive analyst coverage includes upgrades and maintained "outperform" ratings, while institutional investors hold 47.91% of the company, which recently beat earnings expectations.
2026-08-01 12:11:02
Avidity Partners Management LP has acquired a new stake of 10,000 shares, valued at approximately $1.11 million, in Abivax SA Sponsored ADR (NASDAQ:ABVX) during the first quarter. Institutional investors now own 47.91% of the company's stock. Abivax recently reported a narrower-than-expected quarterly loss of $0.71 per share and revenue exceeding analyst estimates, while analysts maintain a "Moderate Buy" rating with a consensus target price of $156.50.
